Market Place
Sourcing Support
Synairgen announces data from the US NIH-led ACTIV-2 Phase 2 trial for SNG001
04 Oct 2022 //
BUSINESSWIRE
Synairgen assessing three clinical options for antiviral drug
29 Sep 2022 //
PROACTIVEINVESTOR
Synairgen to Present COVID Data From Phase 3 SPRINTER Study
20 Sep 2022 //
BUSINESSWIRE
Synairgen announces positive findings from the SG015 trial of SNG001
07 Sep 2022 //
BUSINESSWIRE
Synairgen announces its collaboration the UNIVERSAL trial, an study of patients
05 Sep 2022 //
SYNAIRGEN
Synairgen tests new anti-Covid drug
16 May 2022 //
DAILY ECHO
Synairgen to present at ATS 2022
05 Apr 2022 //
PRESS RELEASE
Synairgen ACTIV-2 trial paused while NIH tweaks study design
05 Mar 2022 //
FIERCEBIOTECH
Synairgen halts Phase III trial of SNG001 for Covid-19 treatment
04 Mar 2022 //
CLINICALTRIALSARENA
Biotech shares eviscerated in wake of Covid-19 flop
22 Feb 2022 //
ENDPTS
Synairgen`s inhalable drug fails study in hospitalised COVID patients
21 Feb 2022 //
REUTERS
Synairgen Partners with Ashfield Engage to Support Commercialization of SNG001
06 Jan 2022 //
CONTRACTPHARMA
Synairgen concludes patient enrolment for Covid-19 trial
13 Nov 2021 //
CLINICALTRIALSARENA
Synairgen concludes patient enrolment for Covid-19 trial
11 Nov 2021 //
CLINICALTRIALSARENA
Synairgen COVID-19 treatment moves to Phase III trials
20 Oct 2021 //
PHARMAFILE
Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3
20 Oct 2021 //
GLOBENEWSWIRE
Synairgen appoints Gareth Walters, Ph.D. as CRO
13 Oct 2021 //
LONDONSTOCKEXCHANGE
Edesa finds a signal in severely ill Covid-19 patients
21 Sep 2021 //
EVALUATE
Synairgen announces results of in vitro studies showing antiviral activity
24 May 2021 //
GLOBENEWSWIRE
Synairgen announces data from Home Cohort of SG016 Phase II trial o
30 Apr 2021 //
GLOBENEWSWIRE
Synairgen announces that dosing has commenced with its inhaled interferon beta
15 Feb 2021 //
GLOBENEWSWIRE
Synairgen’s inhaled COVID-19 treatment included in US trial
10 Feb 2021 //
PHARMATIMES
Synairgen announces inclusion of its inhaled interferon beta in US NIH ACTIV-2
25 Jan 2021 //
GLOBENEWSWIRE
Synairgen concludes recruitment in Covid-19 inhaled drug study
20 Jan 2021 //
CLINICALTRIALSARENA
T-Cure Bioscience and Immunotech Biopharm Ltd Announce License Agreement
20 Jan 2021 //
BUSINESSWIRE
Synairgen announces commencement of dosing in its international Phase III study
12 Jan 2021 //
GLOBENEWSWIRE
Phase III trial to study interferon beta therapy in COVID-19 patients initiated
12 Jan 2021 //
EUROPEANPHARMACEUTICALREVIEW
Synairgen joins with Parexel Biotech to study COVID-19 drug
24 Nov 2020 //
OUTSOURCING-PHARMA
Interferon beta-1a candidate for COPD advances to PhIII to test
13 Nov 2020 //
ENDPTS
Parexel Biotech Collaborates with Synairgen on Pivotal Phase III TriaL
19 Oct 2020 //
GLOBENEWSWIRE
Akron Biotech Signs Agreement With Synairgen plc to Supply Interferon-beta
19 Oct 2020 //
BUSINESSWIRE
Positive COPD data for Synairgen`s SNG001 supports COVID-19 programme
13 Sep 2020 //
PM LIVE
Synairgen announces positive data from analysis of trial in COPD patients
08 Sep 2020 //
GLOBENEWS WIRE
Synairgen shares soar on COVID-19 treatment, but caveats abound
20 Jul 2020 //
FIERCEBIOTECH
Synairgen Completes Recruitment of Hospitalised Patients in COVID-19 Trial
28 May 2020 //
GLOBENEWSWIRE
Synairgen launches SG016 trial of SNG001 for Covid-19 treatment
27 May 2020 //
CLINICALTRIALSARENA
Synairgen launches SG016 trial of SNG001 for Covid-19 treatment
26 May 2020 //
CLINICALTRIALSARENA
Approval received to extend SG016 clinical study of SNG001 in COVID-19
30 Apr 2020 //
SYNAIRGEN
